跳转至内容
Merck
CN

SML0486

依克立达

≥98% (HPLC), powder, ABC transporters MDR-1 (P-gp) inhibitor

别名:

GF120918, GG918, GW0918, N-[4-[2-(3,4-二氢-6,7-二甲氧基-2 (1H)-异喹啉基)乙基] 苯基]-9,10-二氢-5-甲氧基-9-氧代-4-吖啶甲酰胺

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C34H33N3O5
化学文摘社编号:
分子量:
563.64
UNSPSC Code:
12161501
PubChem Substance ID:
NACRES:
NA.77
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

依克立达, ≥98% (HPLC)

SMILES string

COc1cccc2C(=O)c3cccc(C(=O)Nc4ccc(CCN5CCc6cc(OC)c(OC)cc6C5)cc4)c3Nc12

InChI

1S/C34H33N3O5/c1-40-28-9-5-7-26-32(28)36-31-25(33(26)38)6-4-8-27(31)34(39)35-24-12-10-21(11-13-24)14-16-37-17-15-22-18-29(41-2)30(42-3)19-23(22)20-37/h4-13,18-19H,14-17,20H2,1-3H3,(H,35,39)(H,36,38)

InChI key

OSFCMRGOZNQUSW-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL (clear solution, warmed)

shipped in

wet ice

storage temp.

−20°C

Quality Level

Application

依克立达(Elacridar)可用作:
  • 作为化学物质,解释自噬作用与舒尼替尼耐药机制之间的联系
  • 作为 ATP 结合盒 B亚家族1成员的抑制剂,研究其对 NSC23766细胞毒性的作用
  • 处理罗丹明123(Rh123)标记细胞,在荧光激活细胞分选法(FACS)中设置分选门

Biochem/physiol Actions

GF120918(依克立达)是 ABC 转运蛋白 MDR-1 (P-gp) 和 BCRP 的强效抑制剂。GF120918 可增加细胞毒性抗肿瘤药物的生物利用度,也可导致大脑和 CNS 中抗 HIV 药物水平升高。
GF120918(依克立达)是一种 MDR-1 (P-gp) 抑制剂。

Features and Benefits

这种化合物是 ADME 毒性研究的特色产品。点击此处发现更多特色 ADME 毒性产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Tomoteru Yamasaki et al.
Nuclear medicine and biology, 38(5), 707-714 (2011-07-02)
Topotecan (TPT) is a camptothecin derivative and is an anticancer drug working as a topoisomerase-I-specific inhibitor. But TPT cannot penetrate through the blood-brain barrier. In this study, we synthesized a new positron emission tomography (PET) probe, [(11)C]TPT, to evaluate the
Christopher Rowbottom et al.
Pharmacology research & perspectives, 9(2), e00740-e00740 (2021-03-05)
Transporters can play a key role in the absorption, distribution, metabolism, and excretion of drugs. Understanding these contributions early in drug discovery allows for more accurate projection of the clinical pharmacokinetics. One method to assess the impact of transporters in
Thomas Wanek et al.
European journal of nuclear medicine and molecular imaging, 39(1), 149-159 (2011-10-11)
One important mechanism for chemoresistance of tumours is overexpression of the adenosine triphosphate-binding cassette transporter P-glycoprotein (Pgp). Pgp reduces intracellular concentrations of chemotherapeutic drugs. The aim of this study was to compare the suitability of the radiolabelled Pgp inhibitors [(11)C]tariquidar
Hanneke G M Wittgen et al.
Molecular pharmaceutics, 9(5), 1351-1360 (2012-03-21)
Although the CB1 receptor antagonist/inverse agonist rimonabant has positive effects on weight loss and cardiometabolic risk factors, neuropsychiatric side effects have prompted researchers to develop peripherally acting derivatives. Here, we investigated for a series of 3,4-diarylpyrazoline CB1 receptor antagonists if
The xenobiotic transporter Mdr1 enforces T cell homeostasis in the presence of intestinal bile acids
Cao W, et al.
Immunity, 47(6), 1182-1196 (2017)

商品

Discover Bioactive Small Molecules for ADME/Tox

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持